Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-004 plus gemcitabine and docetaxel in metastatic soft tissue sarcoma
NL-OMON39691Phase 2Active, not recruiting
- Sponsor
- Morphotek
- Start
- Apr 2014
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ontuxizumab, gemcitabine and docetaxel in soft tissue sarcoma (STS), sponsored by Morphotek. Started Apr 2014; status: active, not recruiting.
02
Drugs
ontuxizumabgemcitabinedocetaxel
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NL-OMON39691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39691.